Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Regulatory press release

BICO Publishes Annual Report and Sustainability Report 2022

BICO Group
Download the release

BICO Group AB (publ) today publishes its annual report and sustainability report for 2022 on its website.

https://bico.com/investors/financials/financial-reports-and-presentations/

The report describes the company’s business model, market, strategy, and roadmap for growth. It includes detailed coverage of our environment, social and governance engagements and commitment to the UN Global Compact.

”I would like to thank our dedicated and passionate team for the tremendous efforts in 2022, the Board for their steady and crucial guidance, our shareholders for their continued confidence in us, and our amazing customers for their loyalty. We look forward to another year with continued improvements and delivering on our profitable growth strategy.”

Erik Gatenholm, President & CEO BICO Group

For further information, please contact:
Åsa Hillsten, Senior Advisor Investor Relations, BICO Group AB
Phone: +46 70-081 81 17
Email: ash@bico.com

About BICO
BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 11,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction the world’s organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

This information is information that BICO Group is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-03-17 11:00 CET.

Attachments
BICO Annual Report 2022 ENG

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.